Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor specific antigen-loaded dendritic cells
- Development stage
- Unknown
- Lead developer
- Northwest Biotherapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
Tumor specific antigen-loaded dendritic cells are a personalized cancer immunotherapy that utilizes autologous dendritic cells (DCs) loaded with tumor antigens to stimulate an immune response against cancer. This approach involves collecting a patient's own dendritic cells, loading them with tumor-specific antigens (either from tumor lysates, synthetic peptides, tumor-derived mRNA, or other sources), and then reinfusing them into the patient. The loaded DCs present these antigens to T cells, activating them to recognize and attack cancer cells expressing the same antigens. This therapy aims to enhance the body's natural immune response against cancer by improving T-cell priming and generating new or enhanced immune responses.
- Other names
- DC-ATAdendritic cell vaccinationDCVautologous dendritic cells loaded with antigensDC vaccines
02
Targets
γδ TCR (T-cell receptor)CD28 (Cluster of Differentiation 28)LFA-1 (Integrin αLβ2)
Beyond the preview
Go deeper on tumor specific antigen-loaded dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor specific antigen-loaded dendritic cells.